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 This paper opens up to discussion whether some questions, points of view, and doubts counterbalance the belief and do-
gmas that randomized clinical trials (mainly in radiotherapy) should be considered as the only source of guidelines to 
design novel therapeutic standards in radiotherapy. A number of the physics, radiotherapy, clinical radiobiology and ge-
netic and molecular tumor’s characteristics suggest that radiotherapy protocols based on the “evidence based trials” seem 
to be antonymous to individually personalized therapy. The major goal of this paper is to consider and discuss whether 
individually personalized radiotherapy is already attainable and reliable or still remains the exception.
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Introduction
During the previous century, the use of ionizing radiation to 
treat malignant tumors has led to various assessments of the 
effectiveness of radiotherapy (RT): optimistic or rather critical? 
Fulfilled the aims and expectations? mainly successes or some 
disappointments? There is no single and simple unequivocal 
and convincing answer, but it raises some important doubts 
and uncertainties. Subsequently, such a situation presents 
a forum for discussion.
Physics!... physics?
The role of radiotherapy as an effective method of treatment 
for malignant tumors is unquestioned. Technological and me-
thodological progress in this field since its beginning is highly 
impressive (fig. 1). Orthovoltage machines and cobalt “units” 
have been replaced by sophisticated linear accelerators emit-
ting photon and/or electron beams with a wide range of 
energy. Neutron, proton, and recently, boron therapy are all 
being used. Instead of simple planning of the two-dimensional 
isodose distributions of the depth doses, the computerized 3D 
planning systems, e.g. 3, 4D-CRT, IMRT, IART, Vmat, respiratory 
gating and volumetric dose-volume-histograms (DVH) are 
being widely used in daily practice. The general “belief” in the 
system’s individualized reliability and precision is increasingly 
common. Is it certainly unquestioned? Are the doses absorbed 
in the defined target volumes the same as those which were 
planned and reported in the treatment charts? Not necessarily! 
This has been clearly documented by the dosimetry in vivo. 
A relatively high rate of inconsistency has been noted between 
the absorbed and planned dose in the tumor’s target. This fact 
is not a mere suggestion but proof that dosimetry in vivo sho-
uld be an inherent attribute of quality control in radiotherapy 
(RT), but it is still uncommon.
Spatial dose distribution is rarely verified during fractiona-
ted RT, although tumor regression during RT results in chan-
ges in its topography and the surrounding normal tissues. 
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As a consequence, no one can be sure that the high dose 
gradient beyond the tumor’s boundary remains unchanged 
during fractionated radiotherapy, and in fact, it does not (may 
be except bone or maxillary tumors). Tumor regression du-
ring RT usually changes the topography of both the tumor 
and the surrounding normal tissue. As a result, normal tissues 
are shifted into the region of the higher dose than that which 
had been preliminarily planned, and it likely may lead to an 
increased risk of late complications.
Radiotherapy 3D is called “conformal”, which means that 
instead of geometrically regular radiation beams, individually 
shaped beams are adjusted to an irregular tumor’s margins. 
This allows a heterogeneous dose distribution to be achieved; 
high within the tumor volume and with a large gradient in the 
surrounding normal tissue. The other side of this coin is that 
the risk of dose heterogeneity within the gross tumor volume 
(GTV) is often ignored. According to the International Commis-
sion on Radiation Units and Measurements (ICRU) recommen-
dations, dose TD95 (95% isodose) is usually accepted as the GTV 
reference dose. Meanwhile, Fowler [1, 2] definitely pointed out 
that for 3D-RT dose D100 should only be used to cover homo-
geneously the whole GTV volume. An underdose (TD < D100), 
delivered even to a small part of the tumor volume (the so-
-called “cold spot”) almost always ruins preliminarly predicted 
local tumor control probability (TCP) – usually pretty high for 
early T and N0M0  tumors [3, 4]. Withers, Peters and Thames 
[5, 6] convincingly pointed out that in contrary to treatment 
planning and to tumor control expectations, the delivery of 
an extra dose (boost) in such cases can be ineffective, because 
it does not prevent the repair of the biological effects in the 
previous underdosed part of the tumor GTV.
In daily practice, the following two terms of “optimization” 
of RT planning are usually used by radiation oncologists – “dose 
escalation” (DE) and “dose intensity” (DI). The term “optimization” 
means that the planned dose fractionation and the technique 
of irradiation offer the highest effectiveness as possible (the 
highest probability of local tumor control [LTC]). Is this also true 
when only a single RT plan is evaluated? In fact, “optimization” 
is the choice of the best DVH among a few [3–4] RT plans, but 
such a procedure happens rarely.
The term dose escalation is often abused and improperly 
interpreted. This term belongs to physics, and it exclusively 
means an increase in the total dose, e.g. from 60 Gy to 70 Gy 
or to 80 Gy, and nothing else. However, it is generally assumed 
that dose escalation also leads to higher effectiveness of RT, 
which is not true. In conventional radiotherapy, an increase in 
the total dose (TD) is inseparably accompanied by an extension 
of the overall treatment time (OTT). Delivery of 60 Gy needs 
on average OTT of 42 days, 70 Gy – 49 days, 80 Gy – 56 days, 
but the treatment efficacy does not change a lot. 
Meanwhile dose intensity is more clinically important, 
which is the number of Gy delivered per day (or per hour). 
For total doses mentioned earlier, the value of the DI is the 
same, and it equals 1.43 Gy/day. Therefore, it should not be 
surprising that their efficacy is also similar. For the majority 
of epithelial cancers (e.g. in the head and neck region), the 
respective part of the dose-tumor response curve flattens 
(effect plateau) when increasing the DE, resulting in no gain 






































































Figure 1. A key-points in the progress in radiotherapy equipment and techniques during 1900–2020
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in the LTC (fig. 2). What can be expected is a higher risk of 
late complications (which does not depend on the OTT), as 
a result of the accumulation of the higher TD in normal tissue. 
On the contrary, the increase of the DI, e.g. from 1.43 Gy/day 
to 2.0 Gy/day or even 3.0 Gy/day (as a result of shortening the 
OTT) results in higher biological intensity (higher efficacy) of 
the delivered total dose in a shorter OTT. Therefore, it seems 
that DI should be considered as a more clinically useful radio-
biological parameter than a physical one (DE).
Is radiobiology meaningful for radiotherapy 
– yes or not necessarily?
Has radiobiology had any impact on clinical radiotherapy 
or it is only a theoretical field of research? Empirical clini-
cal experience gathered throughout decades has proven 
that radiobiology is the essential and unquestioned basis 
for radiotherapy. The skeptics consider radiobiology as an 
experimental science and research because it uses cell line 
colonies, or transplanted animal tumors, and it does not 
necessarily concern clinical radiotherapy. On the contrary, 
advocates try to argue that radiobiology has always been 
the basis for clinical RT, and all radiobiological mechanisms 
always somehow occur during fractionated RT, but they 
are not clearly manifested; they are hidden in the shadow 
of much more complex and heterogeneous mechanisms 
of radiation response of human tumors than those which 
appear in genetically and morphologically homogenous 
experimental cell lines or animal tumors.
All processes discovered and defined by experimental 
radiobiology always have clinical implications. The scope of 
this article will not permit us to discuss all of them in detail, 
and therefore we will concentrate only on two of them which 
have had a pronounced and undeniable impact on progress 
in clinical radiotherapy. 
The first one is the “time factor”. For a long time (over the 
course of the first 70 years of radiotherapy) there was a ge-
neral belief that the natural growth of the majority of human 
tumors was generally slow, with volume doubling time taking 
about 50–60 days. During 6–7 week fractionated irradiation, 
tumors are unable to double their volume, and therefore the 
time factor had been considered as much less important, 
and usually ignored.
A few retrospective clinical studies [7, 9, 11] in the 1980s 
(not clinical trials) convincingly proved the key-role of tre-
atment time as a major determinant of RT efficacy. It was 
clearly documented that with the extension of the OTT tumor 
cells which survived consecutive dose fractions begin to 
repopulate faster and faster; at the end of the sixth week of 
irradiation cell kill effect of more than a half of 2.0 Gy of the 
daily fraction is counterbalanced by altered repopulation of 
the survived cancer cells. Therefore, after a 2.5-day weekend 
(from Friday afternoon till Monday morning) 10 Gy of the 
previous weekly dose reduces the effective dose to only 
7 Gy. Due to accelerated repopulation of cancer cells, the 
OTT extension by 1 day decreases the LTC probability by 
about 1.5–1.6% [1, 9]. It became obvious that during the 
RT, the natural tumor doubling time of 50–60 days rapidly 
decreases to only 4–5 days. The time factor is no longer being 
ignored but is recognized as a crucial factor to initiate clinical 
studies on various novel altered fractionation regimes with 
the shorter OTT.
The radiobiological “time phenomenon” concerns not only 
RT but also surgery and chemotherapy. If surgery is micro-
scopically non-radical, then the doubling time of cancer cell 
microlesions beyond surgical margins accelerates to about 
10–11 days, similarly as to what happens during the time 
intervals between subsequent chemotherapy cycles. The ge-
neral belief that cancer treatment should begin directly after 
diagnosis, without any unnecessary delay has been commonly 
accepted as the most important prognosticator. However, on 
the contrary, Withers [11] decidedly argued that therapy can be 
delayed and can start even 60 days after diagnosis; the crucial 
point is that once therapy has begun, it should be completed 
in the shortest overall time period as possible. This conclusion 
should be considered as a key-paradigm of radiotherapy and 
combined treatment modalities as well. 
The unquestioned importance of the time factor has led to 
many studies on various fractionation regimes with a shorter 
OTT than conventional. Finally, it has resulted in the revival of 
hypofractionated radiotherapy with high single (10–12 Gy) 
or a few large fraction doses (e.g. 5 x 9 Gy), called “stereotactic 
hypofractionated radiotherapy or radiosurgery (SHRS)”. For 
these regimes, the DI increases from conventional 1.43 Gy/day 
to 9 Gy/day or even 12–20 Gy/day. This also allows for a shor-
tening of the patient’s hospitalization from weeks to days.
The second important contribution radiobiology has made 
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Figure 2. Radiotherapy effectiveness (tumor cure probability – TCP) 
depending on dose escalation (DE) compared with dose intensity 
(DI) [DE = TD + ∆D + ∆OTT; DI = TD/OTT]; TD – total dose; ∆D – dose 
increment; ∆OTT – overall treatment time extension
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expectable but not necessarily achievable. It is difficult to 
understand why such an inaccurate system is still persistently 
used in practice, against all logic and the available genetic, 
molecular and imaging diagnostics. Unfortunately, in such 
situations, the more and more often used term “individually 
personalized radiotherapy” remains unjustified. 
Evidence-based radiotherapy: belief or proven 
facts? 
This is often forced out (belief rather than conviction) that 
the results of randomized clinical trials should be considered 
as the one and only reliable source of facts, which should be 
the basis to design novel, modified therapeutic protocols, 
recommended as obligatory standards.
It is often suggested that the novel “evidence based” stra-
tegies should replace empirical clinical experience and  re-
trospective studies. Some authors believe that the results of 
evidence based studies should be taken for granted, if the 
statistical significance is below 0.05.
Bentzen [4, 17] and Glatstein [18] have convincingly qu-
estioned the logic and reliability of the “result-significance-cer-
tainty-belief” relationships and their impact on the results of 
the trials accepted as “evidence based”. Meta-analyzes of nume-
rous studies on altered radiotherapy and radiochemotherapy 
carried out for head and neck cancers [10, 12, 14] revealed an 
average overall therapeutic gain of only 6%. Should this be 
proof and evidence in favor of altered radiotherapy? If yes, 
immediately the next question arises: which schedule should 
then be recommended? At which tumor stage and localiza-
therapy. The proper choice of dose and fractionation based 
on a given T or N quasi-quantitative ranks might be uncertain. 
There is no doubt that the sole aim of irradiation is to kill all 
cancer cells, which should lead to the irreversible elimina-
tion of two major attributes of malignant cells: immortality 
and repopulation.
Experimental tumor cell cultures in vitro or transplanted 
animal tumors endlessly guarantee these two attributes, due 
to colony forming and the ability to produce subsequent 
generations of descendants, but it (at least immortality) does 
not concern human tumors. They stay alive and grow by 
exploiting the host (patient) as a supplier of nutrients and 
oxygen which the tumor needs to survive. These processes 
last as long as the tumor sponges on the host, but it ultimately 
leads to host death, which automatically causes the tumor’s 
death also. Tumor cell repopulation can be reduced by ra-
diation and/or chemotherapy. The more aggressive therapy 
is the lower and lower chance for tumor cells to produce 
descendants until zero, which results in definitive tumor death, 
whereas the patient will survive and will be cured. To achieve 
such a goal, dose-time fractionation should be tailored to 
the initial number of tumor clonogenic cells. Assuming that 
D10 equals 7 Gy (D10 is the dose which reduces cell survival 
by one decade [e.g.  from 1010 to 109]), then a tumor with 
1010 clonogens needs 11 x 7 Gy (77 Gy) to reduce tumor cell 
survival to on average 10-1 (0.1 cell/tumor), which corresponds 
with the LTC of 90% (TCP = e-0.1 = 0.9). The initial number of 
tumor cells can be easily estimated based on initial tumor 
volume (e.g. GTV), which can be simply counted from serial 
CT scans. Therefore, it seems logical that tumor (or neck node) 
volumetric staging is a proper criterion for tailoring the most 
effective fractionated radiotherapy, instead of the TNM rank 
system “what’s that got to do with anything”. 
The initial number of tumor clonogens varies even within 
a given T category. For example, the initial number of tu-
mor clonogens in the smallest and largest tumors within the 
T2N0M 0 category differs by at least one decade (109.5 vs. 1010.5). 
Therefore, it is logical that the largest tumor should receive 
a total dose higher by at least 7 Gy than the smallest one. 
Meanwhile, in daily practice using “evidence based” protocols, 
the planned total dose is usually the same for different tumor 
volumes within the same T category. While for the smallest 
tumors, 90% TCP can be predicted (e-0.1), whereas for the lar-
gest, within the same T category, the TCP would decrease to 
37% (e-1). If the total dose is tailored based on the T category, 
it should not be surprising that an average overall TCP would 
not be higher than 60–70%, or even less. Therefore, the overall 
TCP will depend on the advantage of smaller or larger tumors 
in the study group (fig. 3). 
The situation becomes even more complex when the 
study group includes patients with various T stage (from T2 to 
T4). As long as the RT protocols are designed based on the TNM 
rank system, therapeutic gain (TCP improvement) will remain 
signicant gain (p < 0.005)
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Figure 3. Theoretical example of a trial showing the effectiveness of the 
arm B > A (evidence based?) occurs untrue and proper statistical analysis 
shows lack of evidence 
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tion? The reliability and strength of such far from unequivocal 
clinical evidence seems uncertain and doubtful. 
Why meta-analyzes included only 19 among the 50 trials 
still remains unexplained; in each arm of these trials there were 
a wide range of various tumor localizations and TNM stages 
recruited. Such huge clinical heterogeneity becomes even 
larger, when the TNM ranks are replaced by tumor volumetric 
staging. Moreover, it is surprising that the local control rates 
noted for the tested arm in some trials were almost the same 
as those for the control arm in other trials. Where is the proof 
of evidence in these trials, if their expected advantage and re-
liability generates so many uncertainties and doubts. The head 
and neck trials are not the only example [19].
Glatstein [18] firmly warned against so-called “tyranny 
of mediana”, which is often used as a measure of treatment 
efficacy. The author pointed out that the 5-year actuarial re-
sults (e.g. survival or local tumor control), match in fact no 
more than 2.5 years of the real time of the follow-up for all 
patients (crude data). The statistics of the actuarial results can 
by itself be often misleading. The results of cases with even 
a short follow-up (even a few days) are not withdrawn but are 
censored. Therefore, only the initial part of the e.g. disease-free 
survival, should be considered as the most reliable. The shorter 
follow-up the lower the credibility of a middle or final part of 
the censored survival curves. This also concerns the median 
values of survival or curability estimated from those parts of 
the survival or local control curve. If, for example, the 5-year 
median value of disease-free survival after the tested therapy 
B would be significantly higher by 25% than that representing 
conventional therapy A (fig. 4), it would likely be recognized 
as evidence based proof that therapy B is significantly more 
effective than therapy A.
However, Bentzen [17] mentioned that high significance it 
is not necessarily unquestionable proof. Instead of the median 
value at the fifth year, careful analysis of a whole course of curve 
A reveals early incidence of failures (recurrences) during the 
first 12 months of the follow-up (fig. 4). It may likely suggest 
that tumor cell microlesions beyond the target volume had 
already existed but passed over the diagnosis (too small to be 
detected), and they were out of the irradiated volume. There-
fore they should not be accounted for in the analysis, because 
they have not had any impact on the results of treatment A. If 
they are ignored then the remaining part of curve A will shift 
closer to curve B, showing in fact no difference in the efficacy 
of both therapies. Therefore, the practical value of such (false) 
preliminarily established evidence is zero.
The majority of cancer patients are treated beyond any 
trials [18], so, why evidence based results of carefully selected 
and randomized trials should be referred to a large number 
of patients who were not recruited to the trials. Bentzen [17] 
has warned that “the lack of significance does not necessarily 
mean the lack of evidence”. Glatstein [18] has pointed out 
that careful and critical interpretation of the retrospective 
results should not be ignored, and sometimes, empirical 
clinical experience and common sense are more important 
than acceptance of the trial’s evidence without criticism 
(caveat emptor).
Belief that randomized trials are the only source of evi-
dence to modify therapeutic modalities might be questioned 
because the methodical rules of the trials create the illusory 
conviction that two or three arms of the trial are biologically 
and clinically homogeneous. Theoretically, the trial could be 
considered as a source of reliable and unquestioned evidence 
based proof, if it includes cases with the same (or within a very 
narrow range) volumetric stage (not TNM) of primary tumor 
(GTV) and total nodal volume (TNM) of the regional nodes in 
each of the trial arms. Apart from that, the prognostic mole-





Early reccurences suggest that cancer microlesion
beyond tumor boundary likely existed before
RT began but they have not been diagnosed and should not
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Figure 4. “TNM tyranny” in clinical trials – randomization and 
stratification without 2 (3) arms based on the TNM system but not on 
volumetric staging do not assure biological homogeneity and identical 
(or at least similar) tumor cell numbers and other molecular and clinical 
predictors. It shows that the results of such a trial may differ
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all patients recruited to the trial. The accomplishment of the 
homogeneity of all biological and clinical factors in all arms of 
the trial is practically unattainable, but if it could be theoreti-
cally possible, patients recruitment will last many years. Such 
an idealized model is still unavailable.
The trials on altered fractionated radiotherapy for head and 
neck cancer enrolled patients with different tumor localizations 
and stages (T2N0–T3N3). The GTV volumes ranged from 0.4 cm3 
to more than 170 cm3. Thus, homogeneity, even within these 
two parameters was none, and the average therapeutic gain 
of 6%, estimated in the meta-analyzes, does not seems reliable, 
but instead misleading. For example, the 5-year DFS gain of 5% 
in the CHART trial, after a 10-year follow-up decreased to 0%. 
This is one of the critical arguments against trials as carriers of 
the “only” evidence based guidance for radiotherapy practice. 
Evidence and proof of what?
Despite the fact that randomized trial results have been 
published in prestigious journals, their reliability and recom-
mendations as “evidence based proof”, unfortunately remains 
uncertain, and therefore they should be very carefully inter-
preted (caveat emptor). 
Individually personalized radiotherapy 
or “evidence based” standard protocols?
Genetic or molecular profiles of malignant human tumors 
have been intensively gathered during the last 10–15 years. 
This has inclined radiation oncologists to utilized them in 
clinical practice to improve treatment efficacy (to increase 
LTC). Growing knowledge on individualized tumors’ geno- 
and fenotypes – even within the same tumor type, stage 
and localization – leads to the expectation that the tailoring 
of individually personalized therapy will be able to replace 
conventional “stiffed” standard protocols. It looks like a belief 
that we are getting closer and closer to finding where the 
goalposts are, whereas the goalposts are always continuously 
moving. Therefore, an accomplishment of the skyline remains 
the illusion only.
It is already well substantiated that cancer cells have de-
veloped various molecular receptors on their surface and 
respective molecular inhibitors have already been produced. 
Cancer cells are however, “smart” enough and they develop a si-
gnaling network which transfer information from the cellular 
membrane receptors to the nucleus in order to survive. When 
one receptor is blocked by the respective inhibitor (e.g. EGFR), 
another signal pathway is automatically activated. Clinical 
studies have shown that the inactivation of a single cancer cell 
receptor is often not enough to cause cell death, and clinical 
expectations can be only partially effective.
A new concept has suggested using a few molecular in-
hibitors (monoclonal antibodies) instead of only one. In 2006, 
two inhibitors – EGFR (cetuximab) and VEGFR (PTK 787/ZK) – 
were used in the MD Cancer Institute in Houston to improve 
radiotherapy for glioblastoma multiforme. Unfortunately, no 
therapeutic gain occurred, but on the contrary, unaccepta-
ble high incidence of serious late complications often led 
to patients’ death. Although glioblastoma cells are able to 
compensate for the block of the two signaling pathways by 
activation of other ways, it has been shown that the patient’s 
tolerance is limited and it does not accept the use of more 
than one molecular inhibitor.
Supporters of “evidence based” therapy will likely be 
outraged that their beliefs on the trial’s evidence is being 
undermined and they will use the argument that, after all, 
the 3D-IMRT, respiratory gating or stereotactic RT are in fact 
nothing more than individualized therapy. It is not easy to 
challenge such a point of view, except that the “individu-
alization” of the 3D physical dose distribution within the 
irradiated volume often disappears when physical doses are 
converted into biological doses and individual tumor biology 
is accounted for. A tumor’s molecular profile as a prerequisite 
for so-called individualized therapy is not very often used. 
For example, although higher radiosensitivity of HPV+ p16+ 
oropharyngeal cancer has been quite well documented, but 
the suggested dose-de-escalation in such cancer patients is 
rather supposed. If someone decides to de-escalate the dose, 
it should be at least restricted to low risk T1–2N0–1 patients. 
A similar situation concerns breast cancer patients. Although 
molecular and hormonal profiles are used to modify the 
standards of combined therapy, radiotherapy is unvaryingly 
tailored to the TNM stage of the disease, what undoubtedly 
is antonymous to the personalized therapy?
In many studies on the geno- and fenotype heterogeneity 
of various human malignant tumors, more and more attention 
is being focused on the reserve pool and the role of cancer 
stem cells (CSC). Their relative higher radioresistance and lower 
lethal effect have already been recognized [21, 22]. If the only 
one CSC would survive radiotherapy, it will become the source 
of permanent tumor regrowth, with the ability to produce ge-
netically mutated metastatic cells. Therefore, the quantitation 
of the size and localization of the CSC-lesions within the tumor 
volume might likely be a key-predictor to optimize mono- or 
combined therapy. Although the identification of CSCs using 
monoclonal antibodies can be partly realized (at least for some 
tumors, e.g. glioblastoma, breast cancer), quantitation of the 
CSC population and its localization within the tumor is not yet 
possible. The genetic plasticity of the CSC makes this situation 
even more complex by the presence and role of hypoxic, apop-
totic and angiogenetic cancer cells. Seemingly, the static tumor 
geno- and fenotype image established during diagnostics is 
unstable, but it is likely changing more or less during therapy. 
At the beginning of therapy, a tumor cell, e.g. type A, during 
subsequent mitotic cell cycles, genetically evolves into the cell 
genetically type B, C, etc., whereas the dose and fractionation 
planning is tailored for the initial profile of the cells A. Therefore, 
if radiotherapy is initially individualized based on the biological 
tumor eye-view, it should be repeated and corrected during 
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treatment, depending on the geno-fenotypic changes, but this 
would be highly expensive and time-consuming. 
A malignant tumor is a family of cells with various functions 
and with multifaceted interactions which have revolted against 
physiological homeostatic mechanisms. Its individualism is 
binary (yes–no) but morphologically, molecularly and func-
tionally unstable. Such a complex of characteristics and inte-
ractions cannot be quantified yet, even by very sophisticated 
computerized systems. This seems unlikely to quantitate some 
regulations among enormous number of variable abnormali-
ties. If it would be possible, then and only then, could attributes 
of individually personalized therapy be fulfilled. Currently this 
term remains unlegitimately abused. Although perspectives 
may look promising, they can be paraphrased by the words 
of the British song “It’s a long, long way to Tipperary”. There are 
still many questions, controversies and uncertainties which 
still wait to be answered. The major message of this likely 
controversial article is that scientific and research progress in 
radiotherapy must be admired, widely recognized and con-
tinued, but the results and conclusions of many studies do 
not always settle an advantage of ones over the others. They 
should be considered with caution and criticism. We must keep 
in mind that common sense, logic and our own professional 
experience are often the most important.
Conflict of interest: none declared
Bogusław Maciejewski 
Maria Sklodowska-Curie National Research Institute of Oncology
Gliwice Branch 
Div. Research Programmes
ul. Wybrzeże Armii Krajowej 15
44-102 Gliwice, Poland
e-mail: boguslaw.maciejewski@io.gliwice.pl 
Received: 21 May 2021 
Accepted: 23 May 2021 
References 
1. Fowler JF, Tomé WA, Fenwick JD, et al. A challenge to traditional radia-
tion oncology. Int J Radiat Oncol Biol Phys. 2004; 60(4): 1241–1256, doi: 
10.1016/j.ijrobp.2004.07.691, indexed in Pubmed: 15519797.
2. Tomé WA, Fowler JF. Selective boosting of tumor subvolumes. Int 
J Radiat Oncol Biol Phys. 2000; 48(2): 593–599, doi: 10.1016/s0360-
3016(00)00666-0, indexed in Pubmed: 10974480.
3. Johnson CR, Thames HD, Huang DT, et al. The tumor volume and 
clonogen number relationship: tumor control predictions based 
upon tumor volume estimates derived from computed tomography. 
Int J Radiat Oncol Biol Phys. 1995; 33(2): 281–287, doi: 10.1016/0360-
3016(95)00119-j, indexed in Pubmed: 7673015.
4. Bentzen SM. Quantitative clinical radiobiology. Acta Oncol. 1993; 32(3): 
259–275, doi: 10.3109/02841869309093594, indexed in Pubmed: 8323764.
5. Withers HR. Biological aspects of conformal therapy. Acta Oncol. 
2000; 39(5): 569–577, doi: 10.1080/028418600750013258, indexed in 
Pubmed: 11093365.
6. Withers HR, Thames HD, Peters LJ. A new isoeffect curve for change in 
dose per fraction. Radiother Oncol. 1983; 1(2): 187–191, doi: 10.1016/
s0167-8140(83)80021-8, indexed in Pubmed: 6680223.
7. Maciejewski B, Withers HR, Taylor JM, et al. Dose fractionation and rege-
neration in radiotherapy for cancer of the oral cavity and oropharynx: 
tumor dose-response and repopulation. Int J Radiat Oncol Biol Phys. 
1989; 16(3): 831–843, doi: 10.1016/0360-3016(89)90503-8, indexed in 
Pubmed: 2921175.
8. Steel GG. Basic clinical radiobiology. 3rd ed. Arnold – Oxford Univ. Press, 
New York 2002: 1–246.
9. Withers HR, Taylor J, Maciejewski B. The hazard of accelerated tumor 
clonogen repopulation during radiotherapy. Acta Oncol. 2009; 27(2): 
131–146, doi: 10.3109/02841868809090333.
10. Maciejewski B, Suwiński R, Blamek S. Radiobiologia kliniczna w radio-
onkologii. Medycyna Praktyczna. 2019: 65–97.
11. Withers HR. Biological bases for modifying conventional fractionation 
regimens in radiotherapy. Strahlentherapie. 1984; 160(11): 670–677, 
indexed in Pubmed: 6506105.
12. Brizel D. Radiotherapy and concurrent chemotherapy for the 
treatment of locally advanced head and neck squamous cell car-
cinoma. Semin Radiat Oncol. 1998; 8(4): 237–246, doi: 10.1016/
s1053-4296(98)80021-0.
13. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin 
Radiat Oncol. 2009; 19(1): 3–10, doi: 10.1016/j.semradonc.2008.09.002, 
indexed in Pubmed: 19028339.
14. Pignon JP, Bourhis J, Domenge C, et al. Chemotherapy added to loco-
regional treatment for head and neck squamous-cell carcinoma: three 
meta-analyses of updated individual data. MACH-NC Collaborative 
Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. 
Lancet. 2000; 355(9208): 949–955, indexed in Pubmed: 10768432.
15. Peters LJ, Wendt CD. Tumor volume as a predictor of radiocurability-
--a drop in the bucket? Int J Radiat Oncol Biol Phys. 1990; 19(2): 497–498, 
doi: 10.1016/0360-3016(90)90565-2, indexed in Pubmed: 2394628.
16. Brenner D. Dose, volume, and tumor-control predictions in radiothera-
py. Int J Radiat Oncol Biol Phys. 1993; 26(1): 171–179, doi: 10.1016/0360-
3016(93)90189-3.
17. Bentzen SM. Towards evidence based radiation oncology: improving 
the design, analysis, and reporting of clinical outcome studies in 
radiotherapy. Radiother Oncol. 1998; 46(1): 5–18, doi: 10.1016/s0167-
8140(97)00226-0, indexed in Pubmed: 9488121.
18. Glatstein E. Personal thoughts on statistic: pitfals or lies, dam lies and 
statistics. Int J Radiat Oncol Biol Phys. 2004; 58: 1329–1333.
19. Fastner G, Gaisberger C, Kaiser J, et al. ESTRO IORT Task Force/ACROP 
recommendations for intraoperative radiation therapy with electrons 
(IOERT) in breast cancer. Radiother Oncol. 2020; 149: 150–157, doi: 
10.1016/j.radonc.2020.04.059, indexed in Pubmed: 32413529.
20. Leemans CR, Brakhuis BJ, Bratzenhoff RH. The molecular biology of 
head and neck cancer. Nat Rev Cancer. 2011; 1: 9–22.
21. Baumann M, Kurth I, Cordes N. Molecular cancer and radiation biology. 
In: Principles and Practice of Radiation Oncology. 7th ed. Wolter and 
Kluwer 2019: 71–86.
22. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells 
in radioresistance. Nat Rev Cancer. 2008; 8(7): 545–554, doi: 10.1038/
nrc2419, indexed in Pubmed: 18511937.
